NEW YORK, March 06, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Invuity, Inc. (NASDAQ:IVTY) securities between July 19, 2016 and November 3, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/invuity-inc. There is no cost or obligation to you.
According to the complaint, throughout the class period Defendants issued materially false and/or misleading statements about its operations and results and misrepresented its ability to sustain its average revenue per account, which serves as a critical metric for the Company's growth.
After the markets closed on November 3, 2016, Invuity revealed its financial results for its third quarter of 2016, lowering its guidance and noting a drop in average revenue per account.
If you suffered a loss in Invuity you have until April 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/invuity-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 



